Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Prostate-associated gene 3 protein (PAGE3) is a member of the cancer/testis antigen family, typically expressed in a range of tumors and normally limited in expression to certain reproductive tissues. PAGE3 is not an enzyme, receptor, or transporter, but rather a non-enzymatic antigen found in various tumors, where it may play roles in cellular stress responses and the regulation of cell proliferation. Its restricted normal tissue expression and upregulation in cancer make it a potential biomarker and immunotherapeutic target for cancers, especially prostate cancer[3]. No small-molecule drugs are known to directly target PAGE3, but it is being investigated as a cancer biomarker and possible target for T-cell-based immunotherapy.
Not established (target is not a common enzyme or receptor; function is antigenic and regulatory)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Prostate-associated gene 3 protein (PAGE3).